Last reviewed · How we verify
CKD-508 Tablet
At a glance
| Generic name | CKD-508 Tablet |
|---|---|
| Sponsor | Chong Kun Dang Pharmaceutical |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Drug-drug Interaction Study to Investigate the Pharmacokinetic Interactions Between CKD-508, Midazolam, and Rosuvastatin in Healthy Adult Male Participants (PHASE1)
- A Study to Investigate the Safety, Tolerability, PK, and PD of CKD-508 in Healthy Participants (PHASE1)
- Evaluation of the Safety and Tolerability of CKD-508 in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CKD-508 Tablet CI brief — competitive landscape report
- CKD-508 Tablet updates RSS · CI watch RSS
- Chong Kun Dang Pharmaceutical portfolio CI